Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

NCT04292223 ↗

Phase 4 Completed 29 enrolled ACADIA Pharmaceuticals Inc.

NaSingle-groupOpen-labelTreatment

Summary

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Timeline

Start: 2020-02-10
Primary completion: 2022-04-26
Completion: 2022-04-26

Outcome

Met primary endpoint

paper Notably, a significant improvement was found on the primary endpoint PMID 38476466 ↗

registry analysis (other test); Pimavanserin 34 mg; p <0.0001; Mean Difference (Final Values) 14.0 (95% CI 8.8 to 19.3); Mixed Models Analysis NCT04292223 ↗

Publications

Evidente VGH, DeKarske D, Coate B, Abler V. The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study. Ther Adv Neurol Disord. 2024 Mar 11;17:17562864241228350. doi: 10.1177/17562864241228350. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pimavanserin	Small molecule	34 mg	Oral